Carasent (CARA.ST) Stock Analysis & AI Equity Report

Software - Application SEK Explore free reports

Carasent (CARA.ST) overview

Carasent (CARA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Carasent reported revenue of SEK 344m and operating profit of SEK 9.4m; the year-end share price was 27.45 SEK and market capitalisation was SEK 1,903m. Carasent is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Carasent's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 808mFY 2025
Share price27.45 SEKFY 2025 year end
RevenueSEK 344mFY 2025
Operating profitSEK 9.4mFY 2025
Net earningsSEK 34.7mFY 2025
Market capitalisationSEK 1,903mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About Carasent

Carasent AB develops and provides mission-critical software for healthcare, rehabilitation and occupational health providers. Its portfolio includes electronic health record and EMR systems, SaaS-based workflow tools, partner integrations, ecosystem services and business intelligence applications. The company focuses on helping customers automate administration, improve operational efficiency and use data to support day-to-day care delivery.

Generate the Carasent report

Carasent is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Carasent and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Carasent

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.